Exploring the “gene–protein–metabolite” network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy
Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD. Methods: Using a strategy that integrated RNA-seq, DIA-based proteom...
Saved in:
Published in | Frontiers in pharmacology Vol. 13; p. 1022627 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
29.11.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 1663-9812 1663-9812 |
DOI | 10.3389/fphar.2022.1022627 |
Cover
Abstract | Background:
According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD.
Methods:
Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a “gene–protein–metabolite” network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay.
Results:
Our findings revealed that the “gene–protein–metabolite” network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome.
Conclusion:
PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 (
Mirzaei et al., 2009
, 95, 740–746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) (
Katus et al., 2017
;
Knuuti, 2019
). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina (
Rousan et al., 2017
). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy (
Shaw et al., 2008
;
Antman and Braunwald, 2020
). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations (
Teng et al., 2016
). TCM has become a principal complement in western countries (
Wieland et al., 2013
). Like “disease” is used in western medicine, “syndrome” is used in TCM to comprehend anomalous human conditions on the basis of patients’ symptoms, tongue, and pulse (
Li et al., 2012
). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has recently emerged as a hot research topic in the TCM field. Objective diagnosis, expert consultations, and efficacy evaluation scales have been developed for PBS syndrome (
Ren et al., 2020
;
Liu et al., 2021
;
Zheng et al., 2022
). The concept of “omics” originates from the genome. It refers to the vocabulary generated by biological molecules at different levels to describe high-sequence molecular biological data resources (
Dai and Shen, 2022
). RNA, protein, and metabolites decipher the essence of complex etiologies, and the integration of transcriptomics, proteomics, and metabolomics are becoming a promising research mode (
Pan et al., 2022
). Multi-omics studies have revealed the biological characteristics of APOE transgenic mice, bronchopulmonary dysplasia, and plant tolerant to heavy metals (
Singh et al., 2016
;
Lal et al., 2018
;
Mohler et al., 2020
). Over the past few years, many academic achievements related to CHD-PBS syndrome have been accrued in the single-omic area. For example, Zhou identified the differential metabolites between PBS syndrome and Qi and Yin deficiency syndrome by using the urine samples of 1072 volunteers. Some of the specific metabolites of PBS syndrome are pyroglutamic acid, glutaric acid, glucose, mannitol, and xanthine (
Zhou et al., 2019
). Li’s metabolomic study suggested that valine, leucine, isoleucine, and glycerol phospholipid metabolism could represent PBS syndrome (
Zheng et al., 2022
). Although some progress has been made in the understanding of PBS syndrome in CHD through the studies conducted, some issues still exist, such as a single-omics level, a lack of in-depth research, an inability to verify each other’s research results, and a lack of validation of research conclusions. Overall, a systematic description of the biological foundation of PBS syndrome is lacking. Thus, the present study utilizes system biology methodologies and constructs a multi-omics network by integrating differential genes, proteins, and metabolites to systematically and comprehensively reveal the biological basis of CHD-PBS syndrome. The current study explored 1) the characteristics of the transcriptome, proteome, and metabolome for CHD-PBS syndrome; 2) the “gene–protein–metabolite” network based on differential genes (DGs), differential proteins (DPs), and differential metabolites (DMs); 3) the key biological process and metabolic pathway most related to PBS syndrome; and 4) quantitative results and the diagnostic potential of biomarkers for PSB syndrome. Materials and methods. Multi-omics sequencing, bioinformatics analysis, and clinical validation research strategy. We collected the blood samples from healthy subjects as well as CHD patients with PBS and non-phlegm and blood stasis (NPBS) syndrome to compare the differences between them by subjecting the samples to the transcriptome, proteome, and metabolomics analyses. Bioinformatics analysis identified differential molecules as well as related biological processes and pathways. Next, the “gene–protein–metabolite” network was constructed using the MetaboAnalyst database, String database, and Cytoscape software. We selected molecules with strong centrality and biological association as potential PBS syndrome biomarkers and recruited more volunteers for further validation by enzyme-linked immunosorbent assay (ELISA). Finally, the ROC curve was utilized to assess the level and diagnostic efficacy of various molecules (
Figure 1)
. |
---|---|
AbstractList | Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD. Methods: Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a "gene-protein-metabolite" network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay. Results: Our findings revealed that the "gene-protein-metabolite" network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome. Conclusion: PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 (Mirzaei et al., 2009, 95, 740-746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) (Katus et al., 2017; Knuuti, 2019). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina (Rousan et al., 2017). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy (Shaw et al., 2008; Antman and Braunwald, 2020). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations (Teng et al., 2016). TCM has become a principal complement in western countries (Wieland et al., 2013). Like "disease" is used in western medicine, "syndrome" is used in TCM to comprehend anomalous human conditions on the basis of patients' symptoms, tongue, and pulse (Li et al., 2012). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has recently emerged as a hot research topic in the TCM field. Objective diagnosis, expert consultations, and efficacy evaluation scales have been developed for PBS syndrome (Ren et al., 2020; Liu et al., 2021; Zheng et al., 2022). The concept of "omics" originates from the genome. It refers to the vocabulary generated by biological molecules at different levels to describe high-sequence molecular biological data resources (Dai and Shen, 2022). RNA, protein, and metabolites decipher the essence of complex etiologies, and the integration of transcriptomics, proteomics, and metabolomics are becoming a promising research mode (Pan et al., 2022). Multi-omics studies have revealed the biological characteristics of APOE transgenic mice, bronchopulmonary dysplasia, and plant tolerant to heavy metals (Singh et al., 2016; Lal et al., 2018; Mohler et al., 2020). Over the past few years, many academic achievements related to CHD-PBS syndrome have been accrued in the single-omic area. For example, Zhou identified the differential metabolites between PBS syndrome and Qi and Yin deficiency syndrome by using the urine samples of 1072 volunteers. Some of the specific metabolites of PBS syndrome are pyroglutamic acid, glutaric acid, glucose, mannitol, and xanthine (Zhou et al., 2019). Li's metabolomic study suggested that valine, leucine, isoleucine, and glycerol phospholipid metabolism could represent PBS syndrome (Zheng et al., 2022). Although some progress has been made in the understanding of PBS syndrome in CHD through the studies conducted, some issues still exist, such as a single-omics level, a lack of in-depth research, an inability to verify each other's research results, and a lack of validation of research conclusions. Overall, a systematic description of the biological foundation of PBS syndrome is lacking. Thus, the present study utilizes system biology methodologies and constructs a multi-omics network by integrating differential genes, proteins, and metabolites to systematically and comprehensively reveal the biological basis of CHD-PBS syndrome. The current study explored 1) the characteristics of the transcriptome, proteome, and metabolome for CHD-PBS syndrome; 2) the "gene-protein-metabolite" network based on differential genes (DGs), differential proteins (DPs), and differential metabolites (DMs); 3) the key biological process and metabolic pathway most related to PBS syndrome; and 4) quantitative results and the diagnostic potential of biomarkers for PSB syndrome. Materials and methods. Multi-omics sequencing, bioinformatics analysis, and clinical validation research strategy. We collected the blood samples from healthy subjects as well as CHD patients with PBS and non-phlegm and blood stasis (NPBS) syndrome to compare the differences between them by subjecting the samples to the transcriptome, proteome, and metabolomics analyses. Bioinformatics analysis identified differential molecules as well as related biological processes and pathways. Next, the "gene-protein-metabolite" network was constructed using the MetaboAnalyst database, String database, and Cytoscape software. We selected molecules with strong centrality and biological association as potential PBS syndrome biomarkers and recruited more volunteers for further validation by enzyme-linked immunosorbent assay (ELISA). Finally, the ROC curve was utilized to assess the level and diagnostic efficacy of various molecules (Figure 1).Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD. Methods: Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a "gene-protein-metabolite" network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay. Results: Our findings revealed that the "gene-protein-metabolite" network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome. Conclusion: PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 (Mirzaei et al., 2009, 95, 740-746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) (Katus et al., 2017; Knuuti, 2019). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina (Rousan et al., 2017). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy (Shaw et al., 2008; Antman and Braunwald, 2020). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations (Teng et al., 2016). TCM has become a principal complement in western countries (Wieland et al., 2013). Like "disease" is used in western medicine, "syndrome" is used in TCM to comprehend anomalous human conditions on the basis of patients' symptoms, tongue, and pulse (Li et al., 2012). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has re Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD. Methods: Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a “gene–protein–metabolite” network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay. Results: Our findings revealed that the “gene–protein–metabolite” network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome. Conclusion: PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 ( Mirzaei et al., 2009 , 95, 740–746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) ( Katus et al., 2017 ; Knuuti, 2019 ). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina ( Rousan et al., 2017 ). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy ( Shaw et al., 2008 ; Antman and Braunwald, 2020 ). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations ( Teng et al., 2016 ). TCM has become a principal complement in western countries ( Wieland et al., 2013 ). Like “disease” is used in western medicine, “syndrome” is used in TCM to comprehend anomalous human conditions on the basis of patients’ symptoms, tongue, and pulse ( Li et al., 2012 ). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has recently emerged as a hot research topic in the TCM field. Objective diagnosis, expert consultations, and efficacy evaluation scales have been developed for PBS syndrome ( Ren et al., 2020 ; Liu et al., 2021 ; Zheng et al., 2022 ). The concept of “omics” originates from the genome. It refers to the vocabulary generated by biological molecules at different levels to describe high-sequence molecular biological data resources ( Dai and Shen, 2022 ). RNA, protein, and metabolites decipher the essence of complex etiologies, and the integration of transcriptomics, proteomics, and metabolomics are becoming a promising research mode ( Pan et al., 2022 ). Multi-omics studies have revealed the biological characteristics of APOE transgenic mice, bronchopulmonary dysplasia, and plant tolerant to heavy metals ( Singh et al., 2016 ; Lal et al., 2018 ; Mohler et al., 2020 ). Over the past few years, many academic achievements related to CHD-PBS syndrome have been accrued in the single-omic area. For example, Zhou identified the differential metabolites between PBS syndrome and Qi and Yin deficiency syndrome by using the urine samples of 1072 volunteers. Some of the specific metabolites of PBS syndrome are pyroglutamic acid, glutaric acid, glucose, mannitol, and xanthine ( Zhou et al., 2019 ). Li’s metabolomic study suggested that valine, leucine, isoleucine, and glycerol phospholipid metabolism could represent PBS syndrome ( Zheng et al., 2022 ). Although some progress has been made in the understanding of PBS syndrome in CHD through the studies conducted, some issues still exist, such as a single-omics level, a lack of in-depth research, an inability to verify each other’s research results, and a lack of validation of research conclusions. Overall, a systematic description of the biological foundation of PBS syndrome is lacking. Thus, the present study utilizes system biology methodologies and constructs a multi-omics network by integrating differential genes, proteins, and metabolites to systematically and comprehensively reveal the biological basis of CHD-PBS syndrome. The current study explored 1) the characteristics of the transcriptome, proteome, and metabolome for CHD-PBS syndrome; 2) the “gene–protein–metabolite” network based on differential genes (DGs), differential proteins (DPs), and differential metabolites (DMs); 3) the key biological process and metabolic pathway most related to PBS syndrome; and 4) quantitative results and the diagnostic potential of biomarkers for PSB syndrome. Materials and methods. Multi-omics sequencing, bioinformatics analysis, and clinical validation research strategy. We collected the blood samples from healthy subjects as well as CHD patients with PBS and non-phlegm and blood stasis (NPBS) syndrome to compare the differences between them by subjecting the samples to the transcriptome, proteome, and metabolomics analyses. Bioinformatics analysis identified differential molecules as well as related biological processes and pathways. Next, the “gene–protein–metabolite” network was constructed using the MetaboAnalyst database, String database, and Cytoscape software. We selected molecules with strong centrality and biological association as potential PBS syndrome biomarkers and recruited more volunteers for further validation by enzyme-linked immunosorbent assay (ELISA). Finally, the ROC curve was utilized to assess the level and diagnostic efficacy of various molecules ( Figure 1) . Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD.Methods: Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a “gene–protein–metabolite” network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay.Results: Our findings revealed that the “gene–protein–metabolite” network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome.Conclusion: PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 (Mirzaei et al., 2009, 95, 740–746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) (Katus et al., 2017; Knuuti, 2019). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina (Rousan et al., 2017). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy (Shaw et al., 2008; Antman and Braunwald, 2020). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations (Teng et al., 2016). TCM has become a principal complement in western countries (Wieland et al., 2013). Like “disease” is used in western medicine, “syndrome” is used in TCM to comprehend anomalous human conditions on the basis of patients’ symptoms, tongue, and pulse (Li et al., 2012). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has recently emerged as a hot research topic in the TCM field. Objective diagnosis, expert consultations, and efficacy evaluation scales have been developed for PBS syndrome (Ren et al., 2020; Liu et al., 2021; Zheng et al., 2022). The concept of “omics” originates from the genome. It refers to the vocabulary generated by biological molecules at different levels to describe high-sequence molecular biological data resources (Dai and Shen, 2022). RNA, protein, and metabolites decipher the essence of complex etiologies, and the integration of transcriptomics, proteomics, and metabolomics are becoming a promising research mode (Pan et al., 2022). Multi-omics studies have revealed the biological characteristics of APOE transgenic mice, bronchopulmonary dysplasia, and plant tolerant to heavy metals (Singh et al., 2016; Lal et al., 2018; Mohler et al., 2020). Over the past few years, many academic achievements related to CHD-PBS syndrome have been accrued in the single-omic area. For example, Zhou identified the differential metabolites between PBS syndrome and Qi and Yin deficiency syndrome by using the urine samples of 1072 volunteers. Some of the specific metabolites of PBS syndrome are pyroglutamic acid, glutaric acid, glucose, mannitol, and xanthine (Zhou et al., 2019). Li’s metabolomic study suggested that valine, leucine, isoleucine, and glycerol phospholipid metabolism could represent PBS syndrome (Zheng et al., 2022). Although some progress has been made in the understanding of PBS syndrome in CHD through the studies conducted, some issues still exist, such as a single-omics level, a lack of in-depth research, an inability to verify each other’s research results, and a lack of validation of research conclusions. Overall, a systematic description of the biological foundation of PBS syndrome is lacking. Thus, the present study utilizes system biology methodologies and constructs a multi-omics network by integrating differential genes, proteins, and metabolites to systematically and comprehensively reveal the biological basis of CHD-PBS syndrome. The current study explored 1) the characteristics of the transcriptome, proteome, and metabolome for CHD-PBS syndrome; 2) the “gene–protein–metabolite” network based on differential genes (DGs), differential proteins (DPs), and differential metabolites (DMs); 3) the key biological process and metabolic pathway most related to PBS syndrome; and 4) quantitative results and the diagnostic potential of biomarkers for PSB syndrome. Materials and methods. Multi-omics sequencing, bioinformatics analysis, and clinical validation research strategy. We collected the blood samples from healthy subjects as well as CHD patients with PBS and non-phlegm and blood stasis (NPBS) syndrome to compare the differences between them by subjecting the samples to the transcriptome, proteome, and metabolomics analyses. Bioinformatics analysis identified differential molecules as well as related biological processes and pathways. Next, the “gene–protein–metabolite” network was constructed using the MetaboAnalyst database, String database, and Cytoscape software. We selected molecules with strong centrality and biological association as potential PBS syndrome biomarkers and recruited more volunteers for further validation by enzyme-linked immunosorbent assay (ELISA). Finally, the ROC curve was utilized to assess the level and diagnostic efficacy of various molecules (Figure 1). According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study aimed to explore the biological basis of PBS syndrome in CHD. Using a strategy that integrated RNA-seq, DIA-based proteomics, and untargeted metabolomics on 90 clinic samples, we constructed a "gene-protein-metabolite" network for CHD-PBS syndrome. We expanded the sample size and validated the differential genes and metabolites in the network through enzyme-linked immunosorbent assay. Our findings revealed that the "gene-protein-metabolite" network of CHD-PBS syndrome included 33 mRNAs, four proteins, and 25 metabolites. JNK1, FOS, CCL2, CXCL8, PTGS2, and CSF1 were all poorly expressed in the PBS group during the sequencing stage, whereas arachidonic acid (AA) was highly expressed. During the validation stage, JNK1, AP-1, CCL2, and CXCL8 were poorly expressed, whereas PTGS2, CSF1, and AA were highly expressed. The area under the receiver operating curve was as follows: CSF1 [0.9635, 95%CI (0.9295, 0.9976)] >JNK1 [0.9361, 95% CI (0.8749, 0.9972)] >CXCL8 [0.8953, 95% CI (0.8222, 0.9684)] > CCL2 [0.8458, 95% CI (0.7676, 0.9241)] >AP-1 [0.7884, 95%CI (0.6869, 0.8899)]. The logistic regression model composed of CSF1 and JNK1 showed the greatest diagnostic value and significance for PBS syndrome. PBS syndrome is characterized by low levels of FOS, AP-1, CCL2, CXCL8, and JNK1 and elevated levels of PTGS2 and CSF1, implying that the AA metabolism is abnormal and that the JNK/AP-1 pathway is inhibited. PBS syndromes, as a subtype of CHD, may have unique molecular changes. Background. Globally, coronary heart disease (CHD) is the leading cause of death, and this would likely continue until 2030 (Mirzaei et al., 2009, 95, 740-746). According to the disease course, CHD can be classified as chronic stable CHD (or chronic coronary syndrome) and acute coronary syndrome (ACS) (Katus et al., 2017; Knuuti, 2019). Although stable CHD is not as lethal as ACS, it has a varied incidence range and patients with CHD have prolonged angina. Some symptoms of stable angina are alleviated with pharmacological therapy, but it cannot eliminate recurrent angina (Rousan et al., 2017). The clinical outcomes were not significantly improved in patients who underwent revascularization compared with those who received optimal pharmacological therapy (Shaw et al., 2008; Antman and Braunwald, 2020). A bottleneck appears to exist in CHD treatment, and traditional Chinese medicine (TCM) can act as a favorable complement. Because of its individualized treatment approach, TCM is widely practiced in eastern civilizations (Teng et al., 2016). TCM has become a principal complement in western countries (Wieland et al., 2013). Like "disease" is used in western medicine, "syndrome" is used in TCM to comprehend anomalous human conditions on the basis of patients' symptoms, tongue, and pulse (Li et al., 2012). On the basis of disease-syndrome diagnose, a TCM doctor can subclassify CHD patients into various categories, such as phlegm and blood stasis (PBS) syndrome, cold congealing and Qi stagnation syndrome, and Qi stagnation and blood stasis syndrome. PBS syndrome has recently emerged as a hot research topic in the TCM field. Objective diagnosis, expert consultations, and efficacy evaluation scales have been developed for PBS syndrome (Ren et al., 2020; Liu et al., 2021; Zheng et al., 2022). The concept of "omics" originates from the genome. It refers to the vocabulary generated by biological molecules at different levels to describe high-sequence molecular biological data resources (Dai and Shen, 2022). RNA, protein, and metabolites decipher the essence of complex etiologies, and the integration of transcriptomics, proteomics, and metabolomics are becoming a promising research mode (Pan et al., 2022). Multi-omics studies have revealed the biological characteristics of APOE transgenic mice, bronchopulmonary dysplasia, and plant tolerant to heavy metals (Singh et al., 2016; Lal et al., 2018; Mohler et al., 2020). Over the past few years, many academic achievements related to CHD-PBS syndrome have been accrued in the single-omic area. For example, Zhou identified the differential metabolites between PBS syndrome and Qi and Yin deficiency syndrome by using the urine samples of 1072 volunteers. Some of the specific metabolites of PBS syndrome are pyroglutamic acid, glutaric acid, glucose, mannitol, and xanthine (Zhou et al., 2019). Li's metabolomic study suggested that valine, leucine, isoleucine, and glycerol phospholipid metabolism could represent PBS syndrome (Zheng et al., 2022). Although some progress has been made in the understanding of PBS syndrome in CHD through the studies conducted, some issues still exist, such as a single-omics level, a lack of in-depth research, an inability to verify each other's research results, and a lack of validation of research conclusions. Overall, a systematic description of the biological foundation of PBS syndrome is lacking. Thus, the present study utilizes system biology methodologies and constructs a multi-omics network by integrating differential genes, proteins, and metabolites to systematically and comprehensively reveal the biological basis of CHD-PBS syndrome. The current study explored 1) the characteristics of the transcriptome, proteome, and metabolome for CHD-PBS syndrome; 2) the "gene-protein-metabolite" network based on differential genes (DGs), differential proteins (DPs), and differential metabolites (DMs); 3) the key biological process and metabolic pathway most related to PBS syndrome; and 4) quantitative results and the diagnostic potential of biomarkers for PSB syndrome. Materials and methods. Multi-omics sequencing, bioinformatics analysis, and clinical validation research strategy. We collected the blood samples from healthy subjects as well as CHD patients with PBS and non-phlegm and blood stasis (NPBS) syndrome to compare the differences between them by subjecting the samples to the transcriptome, proteome, and metabolomics analyses. Bioinformatics analysis identified differential molecules as well as related biological processes and pathways. Next, the "gene-protein-metabolite" network was constructed using the MetaboAnalyst database, String database, and Cytoscape software. We selected molecules with strong centrality and biological association as potential PBS syndrome biomarkers and recruited more volunteers for further validation by enzyme-linked immunosorbent assay (ELISA). Finally, the ROC curve was utilized to assess the level and diagnostic efficacy of various molecules (Figure 1). |
Author | Liu, Yongmei Hu, Jun Yang, Guang Shen, Zinuo Zhou, Siyuan He, Haoqiang Wang, Jie |
AuthorAffiliation | 1 Department of Cardiology , Guang’anmen Hospital , China Academy of Chinese Medical Sciences , Beijing , China 2 School of traditional chinese medicine , Beijing University of Chinese Medicine , Beijing , China |
AuthorAffiliation_xml | – name: 2 School of traditional chinese medicine , Beijing University of Chinese Medicine , Beijing , China – name: 1 Department of Cardiology , Guang’anmen Hospital , China Academy of Chinese Medical Sciences , Beijing , China |
Author_xml | – sequence: 1 givenname: Guang surname: Yang fullname: Yang, Guang – sequence: 2 givenname: Siyuan surname: Zhou fullname: Zhou, Siyuan – sequence: 3 givenname: Haoqiang surname: He fullname: He, Haoqiang – sequence: 4 givenname: Zinuo surname: Shen fullname: Shen, Zinuo – sequence: 5 givenname: Yongmei surname: Liu fullname: Liu, Yongmei – sequence: 6 givenname: Jun surname: Hu fullname: Hu, Jun – sequence: 7 givenname: Jie surname: Wang fullname: Wang, Jie |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36523490$$D View this record in MEDLINE/PubMed |
BookMark | eNp9Ustu1DAUjVARLaU_wAJ5ySZDEjt-bJBQVaBSJTawthznOnFJ7GB7aGfXf2CH4Of6JXg6Q9WywAv76vicc33l87w4cN5BUbysqxXGXLwxy6jCqqmaZlXnjTbsSXFUU4pLwevm4EF9WJzEeFnlhYXAlDwrDjFtG0xEdVT8PLteJh-sG1AaAd3e_BrAwe3NjyX4BNblaoakOj_ZlOHfyEG68uEr8gZpH7xTYYNGUCGh3kZQEdCVTSNaxgmGGSnXo27yvkcxqWgjihvXBz8D6jbIugRDUAl6NK-nZEs_W50paYsNmxfFU6OmCCf787j48v7s8-nH8uLTh_PTdxelJpSnEhNNGG-BClPzjnFgnCpBBeXG0KYzggmmjTBdU0HLK8aJaUTNOsI6qlui8HFxvvPtvbqUS7Bznkl6ZeUd4MMg83hWTyAN0zVudVsxLYiuKi56wEK3LQFDQED2ervzWtbdDL0Gl4eZHpk-vnF2lIP_LgUjhNE6G7zeGwT_bQ0xydlGDdOkHPh1lA1r25ZRgXmmvnrY677J38_NhGZH0MHHGMDcU-pKbkMk70IktyGS-xBlEf9HpG1Syfrte-30P-kfO_jVpA |
CitedBy_id | crossref_primary_10_1093_bib_bbad518 crossref_primary_10_3389_fpsyt_2024_1361177 crossref_primary_10_1186_s13020_025_01085_2 crossref_primary_10_34172_jlms_2023_59 crossref_primary_10_1002_pca_3518 crossref_primary_10_1007_s00604_024_06312_5 crossref_primary_10_2147_DMSO_S491897 crossref_primary_10_1002_bmc_70047 |
Cites_doi | 10.1016/j.cmet.2021.08.014 10.1111/j.1742-4658.2007.05772.x 10.1021/acs.jproteome.8b00799 10.1136/hrt.2008.154856 10.1007/s11302-022-09856-4 10.3892/ijmm.4.3.223 10.1053/j.semperi.2018.09.004 10.1016/j.imbio.2010.06.003 10.1080/17512433.2016.1195263 10.1007/s11684-014-0349-8 10.3389/fphar.2021.664320 10.3389/fpls.2015.01143 10.4049/jimmunol.2100866 10.1194/jlr.M005215 10.1002/jcp.24939 10.1186/s13020-021-00521-3 10.1056/NEJMc2024008 10.3389/fcvm.2022.871142 10.4049/jimmunol.1601330 10.1093/eurheartj/ehx492 10.1007/s13105-021-00812-1 10.1161/01.RES.0000163017.13772.3a 10.1016/j.jare.2018.03.005 10.1080/15384101.2019.1662678 10.1002/med.21847 10.1177/1933719114549845 10.1089/acm.2020.0008 10.1006/jmcc.2001.1351 10.1016/j.freeradbiomed.2021.05.009 10.1016/j.biopha.2018.10.087 10.1186/1749-8546-7-9 10.21037/apm-21-2332 10.1007/s40265-017-0691-7 10.1016/j.atherosclerosis.2018.07.007 10.3892/mmr.2015.4432 10.1007/978-3-642-77377-8_5 10.1016/j.metabol.2022.155213 10.1016/j.biopha.2018.08.004 10.1016/j.cyto.2019.154923 10.1161/CIRCULATIONAHA.107.743963 10.1002/alz.040533 10.3390/antiox8120620 10.1186/2046-4053-2-51 10.1097/FJC.0000000000000769 10.1016/j.amjcard.2009.06.028 10.1042/CS20110234 10.3389/fmed.2022.911861 10.15829/1560-4071-2020-2-3757 10.1111/sji.12840 10.1096/fj.01-0353fje 10.1007/s12012-011-9135-x |
ContentType | Journal Article |
Copyright | Copyright © 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang. Copyright © 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang. 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang |
Copyright_xml | – notice: Copyright © 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang. – notice: Copyright © 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang. 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fphar.2022.1022627 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Yang et al |
EISSN | 1663-9812 |
ExternalDocumentID | oai_doaj_org_article_f7c135c507c94c0089de39c554ef4e9e PMC9744761 36523490 10_3389_fphar_2022_1022627 |
Genre | Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c468t-34c4785e69f18b78e786a96968ff62bf9797cf9fb20e580784f2917b47b6c54a3 |
IEDL.DBID | M48 |
ISSN | 1663-9812 |
IngestDate | Wed Aug 27 01:16:00 EDT 2025 Thu Aug 21 18:39:29 EDT 2025 Fri Sep 05 06:27:26 EDT 2025 Thu Jan 02 22:53:16 EST 2025 Tue Jul 01 02:33:49 EDT 2025 Thu Apr 24 22:59:52 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | traditional Chinese medicine coronary heart disease RNA-seq proteomics phlegm and blood stasis syndrome metabolomics |
Language | English |
License | Copyright © 2022 Yang, Zhou, He, Shen, Liu, Hu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c468t-34c4785e69f18b78e786a96968ff62bf9797cf9fb20e580784f2917b47b6c54a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Edited by: Sheng Guo, Nanjing University of Chinese Medicine, China Kunming Qin, Jiangsu Ocean Universiity, China These authors have contributed equally to this work Reviewed by: Zhi Yong Du, Beijing Anzhen Hospital, Capital Medical University, China |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2022.1022627 |
PMID | 36523490 |
PQID | 2755576938 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_f7c135c507c94c0089de39c554ef4e9e pubmedcentral_primary_oai_pubmedcentral_nih_gov_9744761 proquest_miscellaneous_2755576938 pubmed_primary_36523490 crossref_primary_10_3389_fphar_2022_1022627 crossref_citationtrail_10_3389_fphar_2022_1022627 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-11-29 |
PublicationDateYYYYMMDD | 2022-11-29 |
PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-29 day: 29 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Dai (B5) 2015; 230 Matsumoto (B22) 2007; 274 Roebuck (B33) 1999; 4 Wu (B43) 2021; 16 Mirzaei (B25) 2009; 95 Nakayama (B27) 2022; 208 Zhuang (B52) 2022 Zhang (B47) 2021; 33 Popova (B31) 2011; 216 Yoshiyama (B45) 2001; 33 An (B2) 2019; 18 Li (B19) 2012; 7 Zhou (B50) 2014; 8 Khambhati (B14) 2018; 276 Yang (B44) 2020; 75 Knuuti (B15) 2019; 25 Dewald (B7) 2005; 96 Chou (B4) 2019; 8 Hernández-Aguilera (B12) 2020; 126 Lin (B20) 2015; 12 Rousan (B35) 2017; 77 Teng (B40) 2016; 9 Katus (B13) 2017; 38 Ren (B32) 2020; 26 Singh (B38) 2016; 6 Zhang (B46) 2012; 12 Miao (B24) 2022; 132 Wang (B41) 2018; 59 Du (B8) 2020; 91 Zheng (B48) 2022; 9 Shaw (B37) 2008; 117 Lal (B16) 2018; 42 Mohler (B26) 2020; 16 Zhou (B49) 2019; 18 Hanna (B10) 2018; 11 Pertynska-Marczewska (B30) 2015; 22 Hannemann (B11) 2017; 198 Li (B18) 2021; 77 Leocádio (B17) 2019; 109 Roth (B34) 1992; 181 Liu (B21) 2021; 10 Zhou (B51) 2021; 171 Orn (B28) 2009; 104 Wieland (B42) 2013; 2 Guo (B9) 2021; 12 Dai (B6) 2022; 9 Meijer (B23) 2012; 122 Shaposhnik (B36) 2010; 51 Antman (B3) 2020; 383 Pan (B29) 2022; 42 Taimor (B39) 2001; 15 Al-Kofahi (B1) 2018; 107 |
References_xml | – volume: 33 start-page: 2059 year: 2021 ident: B47 article-title: Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species publication-title: Cell Metab. doi: 10.1016/j.cmet.2021.08.014 – volume: 274 start-page: 2376 year: 2007 ident: B22 article-title: Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production publication-title: FEBS J. doi: 10.1111/j.1742-4658.2007.05772.x – volume: 18 start-page: 1994 year: 2019 ident: B49 article-title: A large-scale, multi-center urine biomarkers identification of coronary heart disease in TCM syndrome differentiation publication-title: J. Proteome Res. doi: 10.1021/acs.jproteome.8b00799 – volume: 95 start-page: 740 year: 2009 ident: B25 article-title: Coronary heart disease epidemics: Not all the same publication-title: Heart doi: 10.1136/hrt.2008.154856 – year: 2022 ident: B52 article-title: Purinergic signaling in myocardial ischemia-reperfusion injury publication-title: Purinergic Signal. doi: 10.1007/s11302-022-09856-4 – volume: 4 start-page: 223 year: 1999 ident: B33 article-title: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: Differential activation and binding of the transcription factors AP-1 and NF-kappaB (review) publication-title: Int. J. Mol. Med. doi: 10.3892/ijmm.4.3.223 – volume: 42 start-page: 425 year: 2018 ident: B16 article-title: Genomics, microbiomics, proteomics, and metabolomics in bronchopulmonary dysplasia publication-title: Semin. Perinatol. doi: 10.1053/j.semperi.2018.09.004 – volume: 216 start-page: 164 year: 2011 ident: B31 article-title: Pro- and anti-inflammatory control of M-CSF-mediated macrophage differentiation publication-title: Immunobiology doi: 10.1016/j.imbio.2010.06.003 – volume: 9 start-page: 1225 year: 2016 ident: B40 article-title: Herbal medicines: Challenges in the modern world. Part 3. China and Japan publication-title: Expert Rev. Clin. Pharmacol. doi: 10.1080/17512433.2016.1195263 – volume: 59 start-page: 539 year: 2018 ident: B41 article-title: Diagnostic criteria for syndrome elements of coronary heart disease angina publication-title: J. Tradit. Chin. Med. – volume: 8 start-page: 337 year: 2014 ident: B50 article-title: Clinical phenotype network: The underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine publication-title: Front. Med. doi: 10.1007/s11684-014-0349-8 – volume: 12 start-page: 664320 year: 2021 ident: B9 article-title: Serum metabolomic analysis of coronary heart disease patients with stable Angina pectoris subtyped by traditional Chinese medicine diagnostics reveals biomarkers relevant to personalized treatments publication-title: Front. Pharmacol. doi: 10.3389/fphar.2021.664320 – volume: 6 start-page: 1143 year: 2016 ident: B38 article-title: Heavy metal tolerance in plants: Role of transcriptomics, proteomics, metabolomics, and ionomics publication-title: Front. Plant Sci. doi: 10.3389/fpls.2015.01143 – volume: 208 start-page: 1146 year: 2022 ident: B27 article-title: Porphyromonas gingivalis gingipains induce cyclooxygenase-2 expression and prostaglandin E2 production via ERK1/2-activated AP-1 (c-Jun/c-Fos) and IKK/NF-κB p65 cascades publication-title: J. I. doi: 10.4049/jimmunol.2100866 – volume: 51 start-page: 1962 year: 2010 ident: B36 article-title: Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis publication-title: J. Lipid Res. doi: 10.1194/jlr.M005215 – volume: 230 start-page: 2108 year: 2015 ident: B5 article-title: Epoxyeicosatrienoic acids regulate macrophage polarization and prevent LPS-induced cardiac dysfunction publication-title: J. Cell. Physiol. doi: 10.1002/jcp.24939 – volume: 16 start-page: 109 year: 2021 ident: B43 article-title: Exploring biological basis of Syndrome differentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy publication-title: Chin. Med. doi: 10.1186/s13020-021-00521-3 – volume: 383 start-page: e66 year: 2020 ident: B3 article-title: Invasive or conservative strategy for stable coronary disease. Reply publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc2024008 – volume: 9 start-page: 871142 year: 2022 ident: B48 article-title: A landscape of metabonomics for intermingled phlegm and blood stasis and its concurrent syndromes in stable Angina pectoris of coronary heart disease publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2022.871142 – volume: 198 start-page: 3605 year: 2017 ident: B11 article-title: The AP-1 transcription factor c-jun promotes arthritis by regulating cyclooxygenase-2 and arginase-1 expression in macrophages publication-title: J. Immunol. doi: 10.4049/jimmunol.1601330 – volume: 38 start-page: 3049 year: 2017 ident: B13 article-title: Early diagnosis of acute coronary syndrome publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehx492 – volume: 77 start-page: 451 year: 2021 ident: B18 article-title: MiR-137 regulates low-intensity shear stress-induced human aortic endothelial cell apoptosis via JNK/AP-1 signaling publication-title: J. Physiol. Biochem. doi: 10.1007/s13105-021-00812-1 – volume: 96 start-page: 881 year: 2005 ident: B7 article-title: CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts publication-title: Circ. Res. doi: 10.1161/01.RES.0000163017.13772.3a – volume: 11 start-page: 23 year: 2018 ident: B10 article-title: Synopsis of arachidonic acid metabolism: A review publication-title: J. Adv. Res. doi: 10.1016/j.jare.2018.03.005 – volume: 18 start-page: 2928 year: 2019 ident: B2 article-title: Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages publication-title: Cell Cycle doi: 10.1080/15384101.2019.1662678 – volume: 42 start-page: 441 year: 2022 ident: B29 article-title: Association predictions of genomics, proteinomics, transcriptomics, microbiome, metabolomics, pathomics, radiomics, drug, symptoms, environment factor, and disease networks: A comprehensive approach publication-title: Med. Res. Rev. doi: 10.1002/med.21847 – volume: 22 start-page: 774 year: 2015 ident: B30 article-title: Relationship of advanced glycation end products with cardiovascular disease in menopausal women publication-title: Reprod. Sci. doi: 10.1177/1933719114549845 – volume: 26 start-page: 729 year: 2020 ident: B32 article-title: A quantitative diagnostic method for phlegm and blood stasis syndrome in coronary heart disease using tongue, face, and pulse indexes: An exploratory pilot study publication-title: J. Altern. Complement. Med. doi: 10.1089/acm.2020.0008 – volume: 33 start-page: 799 year: 2001 ident: B45 article-title: Angiotensin blockade inhibits increased JNKs, AP-1 and NF- kappa B DNA-binding activities in myocardial infarcted rats publication-title: J. Mol. Cell. Cardiol. doi: 10.1006/jmcc.2001.1351 – volume: 171 start-page: 55 year: 2021 ident: B51 article-title: Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2021.05.009 – volume: 109 start-page: 1411 year: 2019 ident: B17 article-title: Low serum levels of CCL2 are associated with worse prognosis in patients with acute coronary syndrome: 2-year survival analysis publication-title: Biomed. Pharmacother. Biomedecine Pharmacother. doi: 10.1016/j.biopha.2018.10.087 – volume: 7 start-page: 9 year: 2012 ident: B19 article-title: Inquiry diagnosis of coronary heart disease in Chinese medicine based on symptom-syndrome interactions publication-title: Chin. Med. doi: 10.1186/1749-8546-7-9 – volume: 10 start-page: 9940 year: 2021 ident: B21 article-title: Study on syndrome differentiation strategy of phlegm and blood stasis syndromes of coronary heart disease based on expert consultation on medical cases publication-title: Ann. Palliat. Med. doi: 10.21037/apm-21-2332 – volume: 77 start-page: 265 year: 2017 ident: B35 article-title: Drug therapy for stable Angina pectoris publication-title: Drugs doi: 10.1007/s40265-017-0691-7 – volume: 276 start-page: 1 year: 2018 ident: B14 article-title: Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2018.07.007 – volume: 12 start-page: 8193 year: 2015 ident: B20 article-title: Candesartan ameliorates acute myocardial infarction in rats through inducible nitric oxide synthase, nuclear factor-κB, monocyte chemoattractant protein-1, activator protein-1 and restoration of heat shock protein 72 publication-title: Mol. Med. Rep. doi: 10.3892/mmr.2015.4432 – volume: 181 start-page: 141 year: 1992 ident: B34 article-title: The biology of CSF-1 and its receptor publication-title: Curr. Top. Microbiol. Immunol. doi: 10.1007/978-3-642-77377-8_5 – volume: 132 start-page: 155213 year: 2022 ident: B24 article-title: Vascular smooth muscle cell c-Fos is critical for foam cell formation and atherosclerosis publication-title: Metabolism. doi: 10.1016/j.metabol.2022.155213 – volume: 107 start-page: 1591 year: 2018 ident: B1 article-title: IL-1β reduces cardiac lymphatic muscle contraction via COX-2 and PGE2 induction: Potential role in myocarditis publication-title: Biomed. Pharmacother. Biomedecine Pharmacother. doi: 10.1016/j.biopha.2018.08.004 – volume: 126 start-page: 154923 year: 2020 ident: B12 article-title: Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors publication-title: Cytokine doi: 10.1016/j.cyto.2019.154923 – volume: 117 start-page: 1283 year: 2008 ident: B37 article-title: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.743963 – volume: 16 start-page: e040533 year: 2020 ident: B26 article-title: Proteomic, metabolomic, and transcriptomic examination of APOE transgenic mice publication-title: Alzheimer's. &. Dement. doi: 10.1002/alz.040533 – volume: 8 start-page: 620 year: 2019 ident: B4 article-title: Anti-atherosclerotic effect of Hibiscus leaf polyphenols against tumor necrosis factor-alpha-induced abnormal vascular smooth muscle cell migration and proliferation publication-title: Antioxidants doi: 10.3390/antiox8120620 – volume: 2 start-page: 51 year: 2013 ident: B42 article-title: Bibliometric and content analysis of the Cochrane Complementary Medicine Field specialized register of controlled trials publication-title: Syst. Rev. doi: 10.1186/2046-4053-2-51 – volume: 75 start-page: 45 year: 2020 ident: B44 article-title: Berberine attenuates cholesterol accumulation in macrophage foam cells by suppressing AP-1 activity and activation of the Nrf2/HO-1 pathway publication-title: J. Cardiovasc. Pharmacol. doi: 10.1097/FJC.0000000000000769 – volume: 104 start-page: 1179 year: 2009 ident: B28 article-title: The chemokine network in relation to infarct size and left ventricular remodeling following acute myocardial infarction publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2009.06.028 – volume: 122 start-page: 421 year: 2012 ident: B23 article-title: Activator protein-1 (AP-1) signalling in human atherosclerosis: Results of a systematic evaluation and intervention study publication-title: Clin. Sci. doi: 10.1042/CS20110234 – volume: 9 start-page: 911861 year: 2022 ident: B6 article-title: Advances and trends in omics technology development publication-title: Front. Med. doi: 10.3389/fmed.2022.911861 – volume: 25 start-page: 119 year: 2019 ident: B15 article-title: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) publication-title: Russ. J. Cardiol. doi: 10.15829/1560-4071-2020-2-3757 – volume: 91 start-page: e12840 year: 2020 ident: B8 article-title: IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation publication-title: Scand. J. Immunol. doi: 10.1111/sji.12840 – volume: 15 start-page: 2518 year: 2001 ident: B39 article-title: Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes publication-title: FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. doi: 10.1096/fj.01-0353fje – volume: 12 start-page: 25 year: 2012 ident: B46 article-title: Toxicological insight from AP-1 silencing study on proliferation, migration, and dedifferentiation of rat vascular smooth muscle cell publication-title: Cardiovasc. Toxicol. doi: 10.1007/s12012-011-9135-x |
SSID | ssj0000399364 |
Score | 2.3832517 |
Snippet | Background:
According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD).... According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD). This study... Background: According to the theory of traditional Chinese medicine, phlegm and blood stasis (PBS) is the pathological basis for coronary heart disease (CHD).... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1022627 |
SubjectTerms | coronary heart disease metabolomics Pharmacology phlegm and blood stasis syndrome proteomics RNA-seq traditional Chinese medicine |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ3NbtQwEIAt1BMXxD-hgAYJ9UKjbhLHjo-AqCokUA-t1FvkTGx2pTa76qaH3PYduCF4uX0SZpxsuosQXLhFiaM4mUlmJp75Rog3clKRV6EwTrCexNKiiq0qatpKkEyKsT60e_v8RZ2cy08X-cVWqy_OCevxwP2DO_IakyxHclvQSCSLZWqXGSQr6Lx0xvHXl8zYVjAVvsFsd5Xsq2QoCjNHfjG1zP9MU6YVpIrbyGxZogDs_5OX-Xuy5Jb1Ob4v7g1uI7zrp_tA3HHNQ3Fw2nOnu0M4uy2jWh7CAZzeEqm7R-L7mGkH5O_BevWD1MatV98CpWHW0NaVa0kduCB5vfoJTZ8cDnMPyIgDe90Bt75uYVjQAf5_C4vppft6BbapISTAA7may9kSNhgEqDoYeRQ1hOTFmMugaUhPxe0ei_Pjj2cfTuKhKUOMUhVtnEmUusidMj4pKl04XSgbEDveq7TyRhuN3vgqnbicYfbSpxQSVlJXCnNpsydir5k37pkAimbyymXaIKI0SMcKy92PFUpUdS0jkWwEVOJALOfGGZclRS4s1DIItWShloNQI_F2PGfR8zr-Ovo9y30cyaztsIM0sBw0sPyXBkbi9UZrSno3ecHFNm5-syxTTXfIzSaLSDzttWi8VKbyNJNmEgm9o187c9k90symgf9NIaDUKnn-Pya_L-7yA-HqytS8EHvt9Y17SW5WW70Kb9Qvn5ku1A priority: 102 providerName: Directory of Open Access Journals |
Title | Exploring the “gene–protein–metabolite” network of coronary heart disease with phlegm and blood stasis syndrome by integrated multi-omics strategy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36523490 https://www.proquest.com/docview/2755576938 https://pubmed.ncbi.nlm.nih.gov/PMC9744761 https://doaj.org/article/f7c135c507c94c0089de39c554ef4e9e |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1663-9812 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1663-9812 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000399364 issn: 1663-9812 databaseCode: M48 dateStart: 20101201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZpCiWX0ne3jzANJZfGzdqWJetQSlsaQiElhyzkZuyxlF3YeLe7DtR_o7-4M_Ij2ZL0ZmxZtjwjzzfSzDdCvJfjglCFwiDEchzIHFWQq7SkoxDJpJjc-XJvJz_V8UT-OE_Ot0Rf7qj7gOtbXTuuJzVZzT_-_tV8pgn_iT1OsreHbjnNmdozipiIIFKRvifuk2WKWMtPOrjv_8xsjT2jVEiGNjBk3No8mju62REPYkWemuQ_9g2z5dn9b4Ok_0ZW3jBVR4_Eww5jwpdWKR6LLVs9EfunLUl1cwBn1zlX6wPYh9Nr-urmqfgzhOUBgUPYIw2zgadzmFXBpa1JazhveQ-qNoIcFg6QeRDyVQNcH7uGbtcHeJEXltO5vbiEvCrBR8kD4dH1bA09VwIUDQykFSX4CMeAc6WpSUud2zwTk6PvZ9-Og65yQ4BSpXUQS5Q6TawyLkwLnVqdqtzz8DinosIZbTQ644pobBNmvJcuIr-xkLpQmMg8fi62q0VlXwoglycpbKwNIkqDdC3NuUSyQomqLOVIhL1gMuxozbm6xjwj94blmnm5ZizXrJPrSHwY7lm2pB7_bf2V5T20ZEJuf2Kxusi6-Z05jWGcIKFrNBIJWJnSxgYJrFknrbEj8a7XlowmMO_K5JVdXK2zSNMIuSJlOhIvWu0ZHtVr30joDb3aeJfNK9Vs6knCyU-UWoWv7uzztdjhUXJeZWTeiO16dWXfEsCqi12_MLHr585fbkQlcw |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+the+%22gene-protein-metabolite%22+network+of+coronary+heart+disease+with+phlegm+and+blood+stasis+syndrome+by+integrated+multi-omics+strategy&rft.jtitle=Frontiers+in+pharmacology&rft.au=Yang%2C+Guang&rft.au=Zhou%2C+Siyuan&rft.au=He%2C+Haoqiang&rft.au=Shen%2C+Zinuo&rft.date=2022-11-29&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=13&rft.spage=1022627&rft_id=info:doi/10.3389%2Ffphar.2022.1022627&rft_id=info%3Apmid%2F36523490&rft.externalDocID=36523490 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |